Seasonal influenza epidemics typically affect 5-15% of the population with mainly upper respiratory tract infections.
On a global basis around 3-5 million cases of severe illness are estimated each year with an associated 250,000 - 500,000 deaths (WHO figures).
Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Recommended groups for influenza vaccination are usually those most vulnerable and include the elderly, very young and those with underlying chronic diseases. In the US, influenza vaccination recommendations now include every person >6 mos.
This DiseaseINFOPACK product is a comprehensive research review detailing on a country-by-country basis all relevant aspects of seasonal influenza disease epidemiology, surveillance infrastructure, vaccine recommendations, vaccine target groups, vaccine suppliers and associated licensed products. Where possible details regarding vaccine volumes (per supplier) are included along with notes on pricing/reimbursement policies. As well as major Western markets the review also covers around 20 emerging market economies in the "Rest of World" (ROW) category.